

		EMLc	ATC codes: <b>L01BC01</b>
Indication	Acute myeloid leukaemia with recurrent genetic abnormalities	ICD11 code: <b>2B30.0</b>	
INN	Cytarabine		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > unspecified: 100 mg in vial powder for injection ; 100 mg per mL in vial		
EML status history	First added in 1979 ( <a href="#">TRS 641</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<span>Cancer</span>		
Wikipedia	<a href="#">Cytarabine</a> 		
DrugBank	<a href="#">Cytarabine</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.

